Committed to Helping Improve Patients’ Lives
On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.
About Amneal + Impax Specialty Business
Our specialty business continues to operate as Impax, delivering proprietary medicines to the U.S. market. We offer a growing portfolio in core therapeutic categories including central nervous system disorders, parasitic infections and other therapeutic areas.
Our specialty products are marketed through our skilled 125+ member Impax Specialty Sales & Marketing Team, who call on neurologists, movement disorder specialists and primary care physicians in key markets throughout the U.S.